BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

ProBioGen AG and Virbac Corporation (VBAC) Signed a Licensing Agreement to use ProBioGen's Novel Avian Cell Line AGE1 for Production of Biological Products


5/31/2007 11:18:06 AM

BERLIN, May 31 /PRNewswire/ -- ProBioGen, Germany, announced today that Virbac has entered into a licensing agreement with ProBioGen to develop biological product candidates using ProBioGen's novel avian cell lines AGE1.

Under the terms of the agreement, Virbac will use the permanent cell lines based on duck retina AGE1.cr and somite cells AGE1.cs developed by ProBioGen as the production platform to develop biologicals. The financial details of the agreement are not disclosed.

"This is a breakthrough in the commercialisation of our avian cell line" said Michael Schlenk, CEO of ProBioGen. "The development of new designer cell lines under the full guidelines of the FDA is a long and challenging process. We are very proud to have developed such a cell line which not only satisfies these stringent requirements, but is also safe and cost effective for vaccine and biological production."

About ProBioGen AG

ProBioGen is a specialist for cell line design, viral vectors, and the manufacture of glycoproteins for the biopharmaceutical industry. The German biotechnology company is headquartered in Berlin. Its range of products and services include the development of highly productive cell lines, the design of novel cell lines from primary tissue, the manufacture of glycoproteins for clinical studies and R&D, as well as the production of viral vectors and antibodies for in vitro diagnostics. ProBioGen possesses the manufacturing authorization for pharmaceutically usable active substances for testing in clinical studies and meets the quality standards recommended by the EU (EMEA) and the FDA. A certified cGMP multipurpose facility is available for contract production of biopharmaceutical active substances. The Company is specialized in mammalian cells and combines the know-how of molecular biology scientists with the experience of experts in cell culture technology and process engineering. ProBioGen thus accompanies its clients from the early development of product candidates up to late clinical testing phase.

ProBioGen Contact: Hing Kin Chan, PhD Goethestrasse 54 13068 Berlin Tel: +49-30-924-006-0 Fax: +49-30-924-006-19 e-mail: hingkin.chan@probiogen.de

ProBiogen AG

CONTACT: ProBioGen Contact: Hing Kin Chan, PhD., Goethestrasse 54, 13068Berlin, Tel: +49-30-924-006-0, Fax: +49-30-924-006-19, e-mail:hingkin.chan@probiogen.de



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES